Vlado Perkovic's Publications

Ohkuma T, Van Gaal L, Shaw W et alii
Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program

Journal articles
2020
Diabetes
Arnott C, Li Q, Kang A et alii
Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Journal articles
2020
Journal of the American Heart Association
Cannon CP, Perkovic V, Agarwal R et alii
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial

Journal articles
2020
Circulation
Neuen BL, Jardine MJ, Perkovic V
Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?

Journal articles
2020
Nephrology
Li JW, Woodward M, Perkovic V et alii
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes

Journal articles
2020
JACC: Heart Failure
Neuen BL, Perkovic V
Pilot trials in nephrology: Establishing a base for large-scale randomized trials

Journal articles
2020
Journal of the American Society of Nephrology
Levey AS, Gansevoort RT, Coresh J et alii
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency

Conference Papers
2020
in American Journal of Kidney Diseases
Smyth B, van den Broek-Best O, Hong D et alii
Varying association of extended hours dialysis with quality of life

Journal articles
2019
Clinical Journal of the American Society of Nephrology
Li JW, Badve SV, Zhou Z et alii
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program

Journal articles
2019
The Lancet Rheumatology
Smyth B, Trongtrakul K, Haber A et alii
Inequities in the global representation of sites participating in large, multicentre dialysis trials: A systematic review

Journal articles
2019
BMJ Global Health
Neuen BL, Young T, Heerspink HJL et alii
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

Journal articles
2019
The Lancet Diabetes and Endocrinology
Oshima M, Jun M, Ohkuma T et alii
The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study

Journal articles
2019
Diabetologia
Neuen BL, Cherney DZ, Jardine MJ et alii
Sodium-glucose cotransporter inhibitors in type 2 diabetes: Thinking beyond glucose lowering

Journal articles
2019
CMAJ
Zhou Z, Jardine M, Perkovic V et alii
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program

Journal articles
2019
Diabetologia
Smyth B, Haber A, Trongtrakul K et alii
Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease: A Meta-analysis

Journal articles
2019
JAMA Internal Medicine
Gray NA, Zuo L, Hong D et alii
Quality of life in caregivers compared with dialysis recipients: The Co-ACTIVE sub-study of the ACTIVE dialysis trial

Journal articles
2019
Nephrology
Perkovic V, Bain SC, Bakris G et alii
Estimated GFR (eGFR) loss with glucagon-like peptide-1 (GLP-1) analogue treatment: data from SUSTAIN 6 and LEADER

Conference Abstracts
2019
in DIABETOLOGIA
Neal B, Li J, Perkovic V et alii
An exploration of factors mediating the effects of canagliflozin on heart failure in patients with type 2 diabetes

Conference Abstracts
2019
in DIABETOLOGIA
Neuen BL, Perkovic V, Ohkuma T et alii
Canagliflozin in patients with type 2 diabetes and macroalbuminuria: data from the CANVAS program

Conference Abstracts
2019
in DIABETOLOGIA
Mahaffey KW, Li J, Badve SV et alii
The effects of canagliflozin on uric acid and gout in patients with type 2 diabetes in the CANVAS programme

Conference Abstracts
2019
in DIABETOLOGIA
Jardine MJ, Mahaffey KW, Perkovic V
Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply

Journal articles
2019
The New England journal of medicine
Inker LA, Heerspink HJL, Tighiouart H et alii
GFR slope as a surrogate end point for kidney disease progression in clinical trials: A meta-analysis of treatment effects of randomized controlled trials

Journal articles
2019
Journal of the American Society of Nephrology
Mahaffey KW, Jardine MJ, Bompoint S et alii
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial

Journal articles
2019
Circulation
Ha JT, Neuen BL, Cheng LP et alii
Benefits and harms of oral anticoagulant therapy in chronic kidney disease

Journal articles
2019
Annals of Internal Medicine
Atkins ER, Perkovic V
Blood pressure: At what level is treatment worthwhile?

Journal articles
2019
Australian Prescriber
Verma S, Mazer CD, Perkovic V
Is it time to REWIND the cardiorenal clock in diabetes?

Journal articles
2019
The Lancet

Vlado Perkovic's Publications

Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program

Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial

Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?

Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes

Pilot trials in nephrology: Establishing a base for large-scale randomized trials

Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency

Varying association of extended hours dialysis with quality of life

The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program

Inequities in the global representation of sites participating in large, multicentre dialysis trials: A systematic review

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study

Sodium-glucose cotransporter inhibitors in type 2 diabetes: Thinking beyond glucose lowering

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program

Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease: A Meta-analysis

Quality of life in caregivers compared with dialysis recipients: The Co-ACTIVE sub-study of the ACTIVE dialysis trial

Estimated GFR (eGFR) loss with glucagon-like peptide-1 (GLP-1) analogue treatment: data from SUSTAIN 6 and LEADER

An exploration of factors mediating the effects of canagliflozin on heart failure in patients with type 2 diabetes

Canagliflozin in patients with type 2 diabetes and macroalbuminuria: data from the CANVAS program

The effects of canagliflozin on uric acid and gout in patients with type 2 diabetes in the CANVAS programme

Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply

GFR slope as a surrogate end point for kidney disease progression in clinical trials: A meta-analysis of treatment effects of randomized controlled trials

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial

Benefits and harms of oral anticoagulant therapy in chronic kidney disease

Blood pressure: At what level is treatment worthwhile?

Is it time to REWIND the cardiorenal clock in diabetes?

The George Institute for Global Health

The George Institute country sites:

Affiliation/s

Acknowledgement of Country